. Author manuscript; available in PMC: 2019 May 1.

Published in final edited form as: J Oral Pathol Med. 2018 Apr 10;47(5):484–491. doi: 10.1111/jop.12705

Table 1. Response of orthotopic FaDu xenografts to Metformin.

Table summarizes the imaging and immunohistochemical measurements obtained from all the experimental studies. Values are reported as mean ± standard error.

Method	Measured Parameter	Control	Metformin	Observation
MRI	Tumor volume (mm³)	315.1 ± 26	233.7 ± 16^*	Significant decrease at d5
PAI	Oxygen saturation (%sO₂)	49.9 ± 3.2	62.3 ± 3.9^*	Significant increase at d5
PAI	HbT (a.u.)	24670 ± 1199	28444 ± 1148^*	Significant increase at d5
Fluorescence imaging (2-DG)	Normalized fluorescence intensity (a.u.)	1211 ± 348	559 ± 192	No significant change
CD31-immunostaining	Microvessel count	131 ± 15	99 ± 13	No significant change
Ki67 immunostaining	H-score	100 ± 2.9	66 ± 3.5^***	Significant reduction

p<0.05

^***

<0.001 between control and treatment groups.